These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 2529814)
1. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Smith SR; Cheesbrough J; Spearing R; Davies JM Antimicrob Agents Chemother; 1989 Aug; 33(8):1193-7. PubMed ID: 2529814 [TBL] [Abstract][Full Text] [Related]
2. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Van der Auwera P; Aoun M; Meunier F Antimicrob Agents Chemother; 1991 Mar; 35(3):451-7. PubMed ID: 1828134 [TBL] [Abstract][Full Text] [Related]
3. Teicoplanin administration in patients experiencing reactions to vancomycin. Smith SR; Cheesbrough JS; Makris M; Davies JM J Antimicrob Chemother; 1989 May; 23(5):810-2. PubMed ID: 2527221 [No Abstract] [Full Text] [Related]
4. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. Van Laethem Y; Hermans P; De Wit S; Goosens H; Clumeck N J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135 [TBL] [Abstract][Full Text] [Related]
5. Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial. Neville LO; Brumfitt W; Hamilton-Miller JM; Harding I Int J Antimicrob Agents; 1995 May; 5(3):187-93. PubMed ID: 18611667 [TBL] [Abstract][Full Text] [Related]
6. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Kureishi A; Jewesson PJ; Rubinger M; Cole CD; Reece DE; Phillips GL; Smith JA; Chow AW Antimicrob Agents Chemother; 1991 Nov; 35(11):2246-52. PubMed ID: 1839490 [TBL] [Abstract][Full Text] [Related]
7. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Cony-Makhoul P; Brossard G; Marit G; Pellegrin JL; Texier-Maugein J; Reiffers J Br J Haematol; 1990 Dec; 76 Suppl 2():35-40. PubMed ID: 2149050 [TBL] [Abstract][Full Text] [Related]
8. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients. Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388 [TBL] [Abstract][Full Text] [Related]
9. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients. Nucci M; Biasoli I; Braggio S; Portugal R; Schaffel R; Maiolino A; Loureiro MM; Spector N; Pulcheri W Oncol Rep; 1998; 5(5):1205-9. PubMed ID: 9683836 [TBL] [Abstract][Full Text] [Related]
10. A prospective randomized study of prophylactic teicoplanin to prevent early Hickman catheter-related sepsis in patients receiving intensive chemotherapy for haematological malignancies. Lim SH; Smith MP; Salooja N; Machin SJ; Goldstone AH J Antimicrob Chemother; 1991 Jul; 28(1):109-16. PubMed ID: 1837550 [TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Svetitsky S; Leibovici L; Paul M Antimicrob Agents Chemother; 2009 Oct; 53(10):4069-79. PubMed ID: 19596875 [TBL] [Abstract][Full Text] [Related]
12. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program. Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016 [TBL] [Abstract][Full Text] [Related]
13. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Gilbert DN; Wood CA; Kimbrough RC Antimicrob Agents Chemother; 1991 Jan; 35(1):79-87. PubMed ID: 1826594 [TBL] [Abstract][Full Text] [Related]
14. Teicoplanin and prophylaxis of Hickman catheter insertions. Lim SH; Smith MP; Machin SJ; Goldstone AH Eur J Surg Suppl; 1992; (567):39-42. PubMed ID: 1381642 [TBL] [Abstract][Full Text] [Related]
15. Teicoplanin in perspective. A critical comparison with vancomycin. Janknegt R Pharm Weekbl Sci; 1991 Aug; 13(4):153-60. PubMed ID: 1834985 [TBL] [Abstract][Full Text] [Related]
16. Teicoplanin in the treatment of infection caused by gram-positive organisms. Williams AH; Grüneberg RN; Webster A; Ridgway GL J Hosp Infect; 1986 Mar; 7 Suppl A():101-3. PubMed ID: 2871091 [TBL] [Abstract][Full Text] [Related]
17. Options and limitations of teicoplanin in febrile granulocytopenic patients. De Pauw BE; Novakova IR; Donnelly JP Br J Haematol; 1990 Dec; 76 Suppl 2():1-5. PubMed ID: 2149042 [TBL] [Abstract][Full Text] [Related]
18. Therapy of infections related to intraperitoneal catheters in patients with ovarian cancer. Meunier F; van der Auwera P; Aoun M; Piccart M; Sculier JP Scand J Infect Dis Suppl; 1990; 72():26-8. PubMed ID: 2151063 [TBL] [Abstract][Full Text] [Related]
19. Use of teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients. Webster A; Russell SJ; Souhami RL; Richards JD; Goldstone AH; Grüneberg RN J Hosp Infect; 1987 Jul; 10(1):77-82. PubMed ID: 2888816 [TBL] [Abstract][Full Text] [Related]
20. A review of the safety profile of teicoplanin. Davey PG; Williams AH J Antimicrob Chemother; 1991 Apr; 27 Suppl B():69-73. PubMed ID: 1829079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]